Document Detail


How to approach genome wars in sepsis?
MedLine Citation:
PMID:  22136332     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
ABSTRACT: Sepsis continues to pose a clear challenge as one of the most difficult and costly problems to treat and prevent. Sepsis is caused by systemic or localized infections that damage the integrity of microcirculation in multiple organs. The challenge of sepsis and its long-term sequelae was addressed by the National Institutes of Health National Heart Lung and Blood Institute Division of Blood Diseases and Resources. Defining sepsis as severe endothelial dysfunction syndrome that causes multiorgan failure in response to intravascular or extravascular microbial agents, the National Heart Lung and Blood Institute panel proposed the concept of genome wars as a platform for new diagnostic, therapeutic, and preventive approaches to sepsis.
Authors:
Jack Hawiger; James M Musser
Publication Detail:
Type:  EDITORIAL     Date:  2011-12-2
Journal Detail:
Title:  Critical care (London, England)     Volume:  15     ISSN:  1466-609X     ISO Abbreviation:  -     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9801902     Medline TA:  Crit Care     Country:  -    
Other Details:
Languages:  ENG     Pagination:  1007     Citation Subset:  -    
Affiliation:
Vanderbilt University School of Medicine, Department of Medicine, Division of Allergy Pulmonary and Critical Care Medicine, 1161 21st Avenue South, T-1218 MCN, Nashville, TN 37232-2650, USA. jack.hawiger@vanderbilt.edu.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  'Any body is better than nobody?' Ethical questions around recruiting and/or retaining health profes...
Next Document:  Decellularization of porcine corneas and repopulation with human corneal cells for tissue-engineered...